← Back
Data updated: Jun 28, 2026
L PERRIGO CO
Generics Pharmaceuticals
L PERRIGO CO is a generic drug manufacturer with 19 FDA-approved products.
1995
Since
19
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
Upcoming FDA Decisions
Full Calendar → Jul 17, 2026 — gedatolisib
6d Jul 23, 2026 — Rivoceranib + camrelizumab
Jul 23, 2026 — Rivoceranib + camrelizumab
L PERRIGO CO's Key Drugs
L PERRIGO CO's core commercial portfolio centers on GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
L PERRIGO CO's Recent FDA Approvals
New NDA/BLA approvals for L PERRIGO CO over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
L PERRIGO CO's Therapeutic Areas
Disease areas where L PERRIGO CO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
L PERRIGO CO Pipeline Snapshot
Active clinical trials for L PERRIGO CO across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 1995-11-22
- Latest
- 2025-10-22
- Applications
- 24